These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypersensitivity reactions to oxaliplatin in two asian patients. Ng CV Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290 [TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment. Kim JJ; Kang J; Hong YS; Kim KP; Kim SY; Kim TW; Kim JE Med Oncol; 2018 Apr; 35(5):65. PubMed ID: 29623500 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions. Park SJ; Lee KY; Park WS; Min SY Oncology; 2013; 85(6):323-7. PubMed ID: 24247529 [TBL] [Abstract][Full Text] [Related]
6. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? Elligers KT; Davies M; Sanchis D; Ferencz T; Saif MW JOP; 2008 Mar; 9(2):197-202. PubMed ID: 18326929 [TBL] [Abstract][Full Text] [Related]
7. Management of allergic reactions to oxaliplatin in colorectal cancer patients. Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322 [TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Gammon D; Bhargava P; McCormick MJ Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639 [TBL] [Abstract][Full Text] [Related]
9. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer. Nozawa H; Muto Y; Yamada Y Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472 [TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Mori Y; Nishimura T; Kitano T; Yoshimura K; Matsumoto S; Kanai M; Hazama M; Ishiguro H; Nagayama S; Yanagihara K; Teramukai S; Chiba T; Sakai Y; Fukushima M Oncology; 2010; 79(1-2):136-43. PubMed ID: 21150228 [TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272 [TBL] [Abstract][Full Text] [Related]
12. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial. Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694 [TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947 [TBL] [Abstract][Full Text] [Related]
14. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. Shao YY; Hu FC; Liang JT; Chiu WT; Cheng AL; Yang CH J Formos Med Assoc; 2010 May; 109(5):362-8. PubMed ID: 20497869 [TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Thomas RR; Quinn MG; Schuler B; Grem JL Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487 [TBL] [Abstract][Full Text] [Related]
16. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Kidera Y; Satoh T; Ueda S; Okamoto W; Okamoto I; Fumita S; Yonesaka K; Hayashi H; Makimura C; Okamoto K; Kiyota H; Tsurutani J; Miyazaki M; Yoshinaga M; Fujiwara K; Yamazoe Y; Moriyama K; Tsubaki M; Chiba Y; Nishida S; Nakagawa K Int J Clin Oncol; 2011 Jun; 16(3):244-9. PubMed ID: 21243395 [TBL] [Abstract][Full Text] [Related]
17. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. Ramanathan RK; Clark JW; Kemeny NE; Lenz HJ; Gococo KO; Haller DG; Mitchell EP; Kardinal CG J Clin Oncol; 2003 Aug; 21(15):2904-11. PubMed ID: 12885808 [TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol. Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137 [TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity reactions to oxaliplatin: what nurses need to know. Bonosky K; Miller R Clin J Oncol Nurs; 2005 Jun; 9(3):325-30. PubMed ID: 15973843 [TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Kim BH; Bradley T; Tai J; Budman DR Oncology; 2009; 76(4):231-8. PubMed ID: 19246947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]